R-ICE + BEAM

R-ICE + BEAM refers to a sequential combination of two multi-agent chemotherapy regimens commonly used in the treatment of aggressive lymphomas, particularly as part of salvage therapy and conditioning prior to autologous stem cell transplantation. **R-ICE** consists of rituximab (a monoclonal antibody targeting CD20 on B-cells), ifosfamide (an alkylating agent), carboplatin (a platinum-based chemotherapeutic), and etoposide (a topoisomerase II inhibitor). Rituximab acts by binding to the CD20 antigen on B lymphocytes, leading to their destruction via immune-mediated mechanisms. The other agents act through DNA damage or inhibition of DNA repair and replication, resulting in cancer cell death[1][2][4]. **BEAM** is a high-dose chemotherapy regimen composed of carmustine (BCNU; an alkylating agent), etoposide, cytarabine (Ara-C; an antimetabolite inhibiting DNA synthesis), and melphalan (an alkylating agent). These drugs work synergistically to eradicate rapidly dividing lymphoma cells before stem cell transplantation[3]. This combined approach is primarily indicated for relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who are eligible for autologous stem cell transplant[5].